1 September 2025 in JCO Oncology Practice
Much work has been published on artificial intelligence (AI) and oncology, with many focusing on an algorithm perspective. However, very few perspective articles have explicitly discussed the role of AI in oncology from the perspectives of the stakeholders—the clinicians and the patients. In this article, we delve into the opportunities of AI in oncology from the clinician's and patient's lens. From the clinician's perspective, we discuss reducing burnout, enhancing decision making, and leveraging vast data sets to provide evidence-based recommendations, eventually affecting diagnostic accuracy and treatment planning. From the patient's perspective, we discuss AI virtual concierge, which could improve the cancer care journey by facilitating patient education, mental health support, and personalized lifestyle wellness recommendations promoting a holistic approach to care. We aim to highlight the stakeholders' unmet needs and guide institutions to create innovative AI solutions in oncology. By addressing these perspectives, our article aims to bridge the gap between technological research advancements and their real-world AI-focused clinical applications in cancer care. Understanding and prioritizing the needs of the stakeholders will foster the development of impactful AI tools and intentional utilization of such technology, with an aim for clinical implementation and integration into workflows.
15 April 2025 in Ultrasonics
18 January 2023 in medRxiv
Anatomical information in ultrasound (US) imaging has not been exploited fully because its wave interference pattern (WIP) has been viewed as speckle noise. We tested the idea that more information can be retrieved by disentangling the WIP rather than discarding it as noise. We numerically solved the forward model of generating US images from computed tomography (CT) images by solving wave-equations using the Stride library. By doing so, we have paved the way for using deep neural networks to be trained on the data generated by the forward model to simulate the solution of the inverse problem, which is generating the CT-style and CT-quality images from a real US image. We demonstrate qualitative features of the generated images that are rich in anatomical details and realism.
31 March 2026 in Clinical Cancer Research
Purpose: Trastuzumab-based chemotherapy has improved outcomes in human epidermal growth factor receptor 2 (HER2)–positive breast cancer, but treatment benefit varies among patients. Predictive signatures are needed to identify patients most likely to respond to these therapies. Experimental Design: We developed Density and Spatial architecture of Tumor-Infiltrating Lymphocytes (DeSTIL), a computational signature derived from hematoxylin and eosin slides. The signature captures spatial organization of immune cells and interactions with nonimmune cells. DeSTIL was trained on HER2+ breast cancer slides from The Cancer Genome Atlas (n = 250) and validated in a phase III National Surgical Adjuvant Breast and Bowel Project (NSABP) B-41 randomized clinical trial (n = 221), which compared chemotherapy plus trastuzumab, lapatinib, or combination. The DeSTIL scores were dichotomized into positive and negative groups, and event-free survival (EFS) was assessed using Cox proportional hazards with interaction terms. Results: In NSABP B-41, DeSTIL-positive patients (n = 61) showed significantly improved event-free survival (EFS) with trastuzumab compared with the combination arm [hazard ratio (HR) = 0.09; 95% confidence interval (CI) = 0.01–0.77; P = 0.006] and a significant signature–treatment interaction (P = 0.024). No EFS difference was observed in DeSTIL-negative patients (n = 160). Gene expression analysis supported the image-derived signature stratifying DeSTIL-positive and DeSTIL-negative tumors. In an exploratory pathologic complete response analysis, a classifier trained on University Hospitals Cleveland slides achieved AUCs of 0.70 in the training cohort and 0.63 in the trastuzumab arm of the NSABP B-41 validation cohort. Conclusions: DeSTIL identifies a subset of HER2+ patients who derive greater benefit from trastuzumab. These findings support the potential of computationally derived immune architecture to inform selection of standard HER2-targeted therapies.